There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well [...]
There are many different types of drugs used for hormone therapy in the treatment of prostate cancer. One of the newer classes of drugs include the GnRH antagonists. Degarelix (aka Firmagon) is the one drug in this class that is currently approved for prostate cancer. Degarelix, like the other hormone therapy drugs, was developed to [...]
Hormone therapy (ADT) is notorious for providing us with side effects. Some of these side effects are best described as ones that deteriorate our general quality of life. For example the most common one we all are familiar with is, of course, hot flashes. You could also add erectile dysfunction as well as loss of [...]
Pamorelin (Trelstar® )is going to become available in the Philippines. Pamorelin, and Decapeptyl® will be made available to urologists and oncologists who treat men with advanced prostate cancer. It will be available in one, three and six month formulations. Pamorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). It is designed to chemically [...]
When taking hormone therapy (ADT) each of us experiences different side effects and each of us experiences them differently. Anyone experiencing hot flashes, probably the most commonly reported side effect of ADT during hormone therapy (ADT) knows how difficult, embarrassing and uncomfortable they can become as you go through your life. Some men, who find [...]
The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is [...]
There is a paradigm shift happening around us in the clinical care of men with metastatic hormone-sensitive prostate cancer. We now know that survival is better when docetaxel chemotherapy is added to androgen-deprivation therapy (ADT), but there have been and still remains concerns about the toxicity of the docetaxel. Recent findings from a new study, [...]
One of the frustrations faced by men in the UK has been the Guideline that restrictes the use of chemotherapy (docetaxel) to only men who have already failed hormone therapy (ADT). This Guideline directly contradicts the current, cutting edge evidence that, in certain circumstances, earlier chemotherapy increases survival. The good news is that the NHS [...]
ASCO GU has given us a number of interesting posters, some of which I have already written about in prior posts. Another of these posters (abstract 232) was about an analysis by Ruessel and colleagues describing cardiovascular events among men with prostate cancer using German claims data. The researchers, in a retrospective study, attempted to [...]
It is commonly known that men on Hormone Therapy (ADT) often experience many physical and psychological side effects from the treatment. Many of my posts have discussed the physical side effects, but I have not adequately explored the adverse psychological side effects that many of us experience when we are on ADT! Besides memory issues [...]
